Sanofi los­es its Ger­man CSO and di­a­betes chief to Grü­nen­thal; Roche touts longterm ad­van­tages of Ocre­vus in treat­ing mul­ti­ple scle­ro­sis

→ Sanofi has lost its glob­al di­a­betes R&D chief and re­gion­al CSO Philip Just Larsen to Ger­man phar­ma gi­ant Grü­nen­thal, leav­ing the com­pa­ny in a lurch to fill his shoes at the com­pa­ny’s Frank­furt of­fice. At Grü­nen­thal, Larsen will serve as chief sci­en­tif­ic of­fi­cer, where he will get to flex his neu­ro back­ground.

“As an MD PhD with clin­i­cal neu­rol­o­gy ex­per­tise, I have first-hand ex­pe­ri­ence in pain man­age­ment, the core com­pe­tence at Grü­nen­thal,” Larsen said in a state­ment. “I am thrilled to con­tribute to the de­vel­op­ment of in­no­v­a­tive med­i­cines for high un­met med­ical needs in pain.” Be­fore join­ing Grü­nen­thal, Larsen spent six years at Sanofi — first as SVP and glob­al head of its di­a­betes di­vi­sion, and lat­er as CSO of the Ger­man hub in ad­di­tion to his for­mer role.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER